JP2005519877A - Ｈｉｖ感染のための幹細胞スクリーニングおよび移植治療 - Google Patents
Ｈｉｖ感染のための幹細胞スクリーニングおよび移植治療 Download PDFInfo
- Publication number
- JP2005519877A JP2005519877A JP2003546840A JP2003546840A JP2005519877A JP 2005519877 A JP2005519877 A JP 2005519877A JP 2003546840 A JP2003546840 A JP 2003546840A JP 2003546840 A JP2003546840 A JP 2003546840A JP 2005519877 A JP2005519877 A JP 2005519877A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hiv
- polymorphism
- gene
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 90
- 208000031886 HIV Infections Diseases 0.000 title claims abstract description 24
- 208000037357 HIV infectious disease Diseases 0.000 title claims abstract description 20
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims abstract description 20
- 238000012216 screening Methods 0.000 title claims abstract description 15
- 238000002054 transplantation Methods 0.000 title description 9
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 140
- 210000004027 cell Anatomy 0.000 claims abstract description 92
- 230000009286 beneficial effect Effects 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 83
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 239000003446 ligand Substances 0.000 claims abstract description 11
- 208000010648 susceptibility to HIV infection Diseases 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 27
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 27
- 210000002865 immune cell Anatomy 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 102000005962 receptors Human genes 0.000 claims description 21
- 108020003175 receptors Proteins 0.000 claims description 21
- 108700028369 Alleles Proteins 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 210000004700 fetal blood Anatomy 0.000 claims description 13
- 210000005260 human cell Anatomy 0.000 claims description 10
- 210000000577 adipose tissue Anatomy 0.000 claims description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 9
- 230000003169 placental effect Effects 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 210000005259 peripheral blood Anatomy 0.000 claims description 8
- 239000011886 peripheral blood Substances 0.000 claims description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims description 5
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims description 5
- 102000043129 MHC class I family Human genes 0.000 claims description 5
- 108091054437 MHC class I family Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 108091054438 MHC class II family Proteins 0.000 claims description 4
- 102000043131 MHC class II family Human genes 0.000 claims description 4
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 238000002825 functional assay Methods 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 208000015181 infectious disease Diseases 0.000 abstract description 18
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 208000011580 syndromic disease Diseases 0.000 abstract description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 69
- 102000054765 polymorphisms of proteins Human genes 0.000 description 21
- 150000007523 nucleic acids Chemical group 0.000 description 17
- 230000035772 mutation Effects 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 206010061818 Disease progression Diseases 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 230000005750 disease progression Effects 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 7
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 229940076144 interleukin-10 Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004941 influx Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 3
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010083930 HIV Receptors Proteins 0.000 description 3
- 102000006481 HIV Receptors Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- -1 CCR2b Proteins 0.000 description 2
- 102000004274 CCR5 Receptors Human genes 0.000 description 2
- 108010017088 CCR5 Receptors Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 description 2
- 108010055165 Chemokine CCL4 Proteins 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 101100240347 Mus musculus Nectin2 gene Proteins 0.000 description 2
- 102100023064 Nectin-1 Human genes 0.000 description 2
- 101710043845 Nectin-1 Proteins 0.000 description 2
- 102100035488 Nectin-2 Human genes 0.000 description 2
- 101100462611 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prr-1 gene Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 102200026935 rs80356669 Human genes 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- 102000004497 CCR2 Receptors Human genes 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 101150075508 Dr gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100023416 G-protein coupled receptor 15 Human genes 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000829794 Homo sapiens G-protein coupled receptor 15 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100031952 Protein 4.1 Human genes 0.000 description 1
- 101710196266 Protein 4.1 Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 229940123627 Viral replication inhibitor Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000003204 nucleic acid hybridization-based method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/998,832 US20030099621A1 (en) | 2001-11-29 | 2001-11-29 | Stem cell screening and transplantation therapy for HIV infection |
| PCT/US2002/038436 WO2003045335A2 (en) | 2001-11-29 | 2002-11-27 | Stem cell screening and transplantation therapy for hiv infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009284587A Division JP5675088B2 (ja) | 2001-11-29 | 2009-12-15 | Ｈｉｖ感染に対する幹細胞スクリーニングおよび移植治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519877A true JP2005519877A (ja) | 2005-07-07 |
| JP2005519877A5 JP2005519877A5 (ja) | 2010-02-12 |
Family
ID=25545599
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546840A Withdrawn JP2005519877A (ja) | 2001-11-29 | 2002-11-27 | Ｈｉｖ感染のための幹細胞スクリーニングおよび移植治療 |
| JP2009284587A Expired - Lifetime JP5675088B2 (ja) | 2001-11-29 | 2009-12-15 | Ｈｉｖ感染に対する幹細胞スクリーニングおよび移植治療 |
| JP2012215505A Expired - Fee Related JP5829993B2 (ja) | 2001-11-29 | 2012-09-28 | Ｈｉｖ感染に対する幹細胞スクリーニングおよび移植治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009284587A Expired - Lifetime JP5675088B2 (ja) | 2001-11-29 | 2009-12-15 | Ｈｉｖ感染に対する幹細胞スクリーニングおよび移植治療 |
| JP2012215505A Expired - Fee Related JP5829993B2 (ja) | 2001-11-29 | 2012-09-28 | Ｈｉｖ感染に対する幹細胞スクリーニングおよび移植治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20030099621A1 (enExample) |
| EP (1) | EP1469888B1 (enExample) |
| JP (3) | JP2005519877A (enExample) |
| AU (1) | AU2002353006A1 (enExample) |
| WO (1) | WO2003045335A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101042448B1 (ko) | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법 |
| WO2007016372A2 (en) * | 2005-07-28 | 2007-02-08 | Eden Biotech Ltd. | Method for regenerating an immune system |
| PT3255061T (pt) * | 2006-11-03 | 2021-07-26 | Univ Leland Stanford Junior | Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto |
| PT2164993T (pt) | 2007-05-29 | 2017-01-12 | Reid Christopher B | Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih |
| CA2840540A1 (en) * | 2011-06-29 | 2013-01-03 | Ronilu Development Corporation | Prevention and treatment of hiv infection |
| WO2014151994A1 (en) | 2013-03-15 | 2014-09-25 | Kambiz Shekdar | Genome editing using effector oligonucleotides for therapeutic treatment |
| RU2563172C1 (ru) * | 2014-11-12 | 2015-09-20 | Общество с ограниченной ответственностью "Покровский банк стволовых клеток" | СПОСОБ ОПРЕДЕЛЕНИЯ АЛЛЕЛЬНОГО ПОЛИМОРФИЗМА CCR5 delta 32 |
| US10426796B2 (en) * | 2016-06-13 | 2019-10-01 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
| US10456423B2 (en) | 2016-06-13 | 2019-10-29 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
| CA3053129A1 (en) * | 2017-02-10 | 2018-08-16 | Abraham J And Phyllis Katz Cord Blood Foundation | Methods of treating hiv infection with allogeneic ccr5 null umbilical cord blood cells |
| ES2954311T3 (es) * | 2017-04-01 | 2023-11-21 | Avm Biotechnology Llc | Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular |
| CA3082404A1 (en) * | 2017-11-15 | 2019-05-23 | Weird Science Llc | Methods and compositions for non-myeloablative bone marrow reconstitution |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05502218A (ja) * | 1989-09-14 | 1993-04-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 治療用組成物；ｈｉｖ感染の治療方法 |
| US6153431A (en) * | 1997-05-30 | 2000-11-28 | Fond Mondiale Rech & Prev Sida | Human immunodeficiency virus co-receptor variants associated with resistance to virus infection |
| WO2001058916A2 (en) * | 2000-02-09 | 2001-08-16 | Human Genome Sciences, Inc. | Antibodies to ccr5 |
| JP2001514886A (ja) * | 1997-08-14 | 2001-09-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｃｃｒ２遺伝子のミスセンス対立遺伝子によるａｉｄｓへの進行の遅延 |
| JP2001518289A (ja) * | 1997-09-29 | 2001-10-16 | ニューロスフィアーズ ホウルディングス リミテッド | 多分化能神経幹細胞からの造血細胞の生成 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US6217867B1 (en) * | 1993-09-13 | 2001-04-17 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US20030017587A1 (en) * | 2001-07-18 | 2003-01-23 | Rader William C. | Embryonic stem cells, clinical applications and methods for expanding in vitro |
-
2001
- 2001-11-29 US US09/998,832 patent/US20030099621A1/en not_active Abandoned
-
2002
- 2002-11-27 EP EP02789972.3A patent/EP1469888B1/en not_active Expired - Lifetime
- 2002-11-27 AU AU2002353006A patent/AU2002353006A1/en not_active Abandoned
- 2002-11-27 JP JP2003546840A patent/JP2005519877A/ja not_active Withdrawn
- 2002-11-27 WO PCT/US2002/038436 patent/WO2003045335A2/en not_active Ceased
- 2002-11-27 US US10/498,450 patent/US20050220772A1/en not_active Abandoned
-
2009
- 2009-12-15 JP JP2009284587A patent/JP5675088B2/ja not_active Expired - Lifetime
-
2012
- 2012-09-28 JP JP2012215505A patent/JP5829993B2/ja not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05502218A (ja) * | 1989-09-14 | 1993-04-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 治療用組成物；ｈｉｖ感染の治療方法 |
| US6153431A (en) * | 1997-05-30 | 2000-11-28 | Fond Mondiale Rech & Prev Sida | Human immunodeficiency virus co-receptor variants associated with resistance to virus infection |
| JP2001514886A (ja) * | 1997-08-14 | 2001-09-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｃｃｒ２遺伝子のミスセンス対立遺伝子によるａｉｄｓへの進行の遅延 |
| JP2001518289A (ja) * | 1997-09-29 | 2001-10-16 | ニューロスフィアーズ ホウルディングス リミテッド | 多分化能神経幹細胞からの造血細胞の生成 |
| WO2001058916A2 (en) * | 2000-02-09 | 2001-08-16 | Human Genome Sciences, Inc. | Antibodies to ccr5 |
Non-Patent Citations (6)
| Title |
|---|
| JPN6009029321, ＡＬＩＶＥ，Ｓ．Ｔ． ｅｔ ａｌ, "Ｇｅｎｅｔｉｃ ｒｅｓｔｒｉｃｔｉｏｎ ｏｆ ＡＩＤＳ ｐａｔｈｏｇｅｎｅｓｉｓ ｂｙ ａｎ ＳＤＦ−１ ｃｈｅｍｏｋｉｎｅ ｇｅｎｅ ｖａｒｉａｎｔ", Ｓｃｉｅｎｃｅ, 1998, Ｖｏｌ．２７９， Ｎｏ．５３４９, ｐ．３８９−９３ * |
| JPN6009029323, ＬＩＵ，Ｈ． ｅｔ ａｌ, "Ｐｏｌｙｍｏｒｐｈｉｓｍ ｉｎ ＲＡＮＴＥＳ ｃｈｅｍｏｋｉｎｅ ｐｒｏｍｏｔｅｒ ａｆｆｅｃｔｓ ＨＩＶ−１ ｄｉｓｅａｓｅ ｐｒｏｇｒｅｓｓｉｏｎ", Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ Ｕ Ｓ Ａ, 1999, Ｖｏｌ．９６， Ｎｏ．８, ｐ．４５８１−５ * |
| JPN6009029325, ＦＬＯＲＥＳ−ＶＩＬＬＡＮＵＥＶＡ，Ｐ．Ｏ． ｅｔ ａｌ, "Ｃｏｎｔｒｏｌ ｏｆ ＨＩＶ−１ ｖｉｒｅｍｉａ ａｎｄ ｐｒｏｔｅｃｔｉｏｎ ｆｒｏｍ ＡＩＤＳ ａｒｅ ａｓｓｏｃｉａｔｅｄ ｗｉｔｈ ＨＬＡ−Ｂｗ４ ｈｏｍｏｚｙｇｏｓｉｔｙ", Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ Ｕ Ｓ Ａ, 200104, Ｖｏｌ．９８， Ｎｏ．９, ｐ．５１４０−５ * |
| JPN6010024842, ＳＡＭＳＯＮ，Ｍ． ｅｔ ａｌ, "Ｒｅｓｉｓｔａｎｃｅ ｔｏ ＨＩＶ−１ ｉｎｆｅｃｔｉｏｎ ｉｎ ｃａｕｃａｓｉａｎ ｉｎｄｉｖｉｄｕａｌｓ ｂｅａｒｉｎｇ ｍｕｔａｎｔ ａｌｌｅｌｅｓ ｏｆ ｔｈｅ ＣＣＲ−５ ｃｈｅｍｏｋｉｎｅ", Ｎａｔｕｒｅ, 1996, Ｖｏｌ．３８２， Ｎｏ．６５９３, ｐ．７２２−５ * |
| JPN6010024843, ＴＡＭＡＳＡＵＳＫＡＳ，Ｄ． ｅｔ ａｌ, "Ａ ｈｏｍｏｌｏｇｏｕｓ ｎａｔｕｒａｌｌｙ ｏｃｃｕｒｒｉｎｇ ｍｕｔａｔｉｏｎ ｉｎ Ｄｕｆｆｙ ａｎｄ ＣＣＲ５ ｌｅａｄｉｎｇ ｔｏ ｒｅｄｕｃｅｄ ｒｅｃｅｐｔｏｒ ｅｘｐｒｅｓｓｉｏｎ", Ｂｌｏｏｄ, 2001, Ｖｏｌ．９７， Ｎｏ．１１, ｐ．３６５１−４ * |
| JPN6010024845, ＯＭＥＴＴＯ，Ｌ． ｅｔ ａｌ, "Ｐｏｌｙｍｏｒｐｈｉｓｍｓ ｉｎ ｔｈｅ ＣＣＲ５ ｐｒｏｍｏｔｅｒ ｒｅｇｉｏｎ ｉｎｆｌｕｅｎｃｅ ｄｉｓｅａｓｅ ｐｒｏｇｒｅｓｓｉｏｎ ｉｎ ｐｅｒｉｎａｔａｌｌｙ ｈｕｍａｎ ｉｍｍｕｎｏｄ", Ｊ Ｉｎｆｅｃｔ Ｄｉｓ, 2001, Ｖｏｌ．１８３， Ｎｏ．５, ｐ．８１４−８ * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5675088B2 (ja) | 2015-02-25 |
| EP1469888B1 (en) | 2016-06-08 |
| EP1469888A4 (en) | 2005-01-19 |
| WO2003045335A3 (en) | 2003-10-16 |
| JP2013031450A (ja) | 2013-02-14 |
| US20050220772A1 (en) | 2005-10-06 |
| US20030099621A1 (en) | 2003-05-29 |
| JP5829993B2 (ja) | 2015-12-09 |
| AU2002353006A1 (en) | 2003-06-10 |
| JP2010116400A (ja) | 2010-05-27 |
| WO2003045335A2 (en) | 2003-06-05 |
| EP1469888A2 (en) | 2004-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5675088B2 (ja) | Ｈｉｖ感染に対する幹細胞スクリーニングおよび移植治療 | |
| EDGARDO et al. | Tissue Acceptance | |
| Williams et al. | Hanging in the balance | |
| Li et al. | STAT1 is essential for HSC function and maintains MHCIIhi stem cells that resist myeloablation and neoplastic expansion | |
| Naif | Pathogenesis of HIV infection | |
| Conley et al. | Genetic analysis of patients with defects in early B‐cell development | |
| Lee et al. | Memory CD4+ T-cells expressing HLA-DR contribute to HIV persistence during prolonged antiretroviral therapy | |
| Rajalingam | Human diversity of killer cell immunoglobulin-like receptors and disease | |
| Bogunia-Kubik et al. | CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | |
| Basílio-Queirós et al. | Natural killer cells-from innate cells to the discovery of adaptability | |
| Kiani et al. | HLA-F on HLA-null 721.221 cells activates primary NK cells expressing the activating killer Ig-like receptor KIR3DS1 | |
| Blaak et al. | Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and β-chemokine production | |
| JP2005519877A5 (ja) | Hiv感染に対する幹細胞スクリーニングおよび移植治療 | |
| Soriano et al. | Polymorphisms in the interleukin-4 receptor α chain gene influence susceptibility to HIV-1 infection and its progression to AIDS | |
| Molitor‐Dart et al. | Tolerance induction or sensitization in mice exposed to noninherited maternal antigens (NIMA) | |
| Gonzalez et al. | Identification and frequency of CCR5Δ32/Δ32 HIV‐resistant cord blood units from Houston area hospitals | |
| Kurd et al. | Molecular determinants and heterogeneity of tissue-resident memory CD8+ T lymphocytes revealed by single-cell RNA sequencing | |
| Bostik et al. | Innate immune natural killer cells and their role in HIV and SIV infection | |
| Hütter et al. | Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion | |
| Kahia | Defining early CD8+ T cell responses during acute and chronic viral infection using single-cell RNA-seq analysis | |
| Elmzzahi | Molecular determinants of brain-resident CD8+ T cells in health and disease | |
| Christmas | Human Leucocyte Antigen-G (HLA-G) 3’UTR Genetic Polymorphisms associate with HIV-1 High-Risk Seronegative Status in the Amsterdam Cohorts Studies | |
| Alyami | Human Leucocyte Antigen-G (HLA-G) 3’UTR Genetic Polymorphisms associate with HIV-1 High-Risk Seronegative Status in the Amsterdam Cohorts Studies | |
| Rokan | The Evolution of a Transplantable Tumour | |
| Vogg | Selection of Γδ T Cells and Their Immune Response Against Murine Cytomegalovirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051115 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090615 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090914 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091215 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20091215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100507 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100805 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100812 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20101117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101117 |